TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Quality of life affected by voiding disorders
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete resolution of the persisting lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage reduction in the lesion's mean area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-day average pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-day MME consumed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: LLFDI function total score at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: clinical dentin‐desensitizing effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of post‐treatment polyphasic potentials of voluntary activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase in post‐treatment duration of voluntary activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in overall disease perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of primary safety events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of ischemic stroke, myocardial infarction, and death from other vascular causes
Endpoint domain: Mortality/survival
Primary endpoint: Recognition of fearful facial expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discriminability of fearful facial expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Misclassifications of fearful facial expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HKAA towards neutral
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion size percent reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regression of WSL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescence intensity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PWV increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: intracranial haemorrhage growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: average max heart dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: average mean heart dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: average mean left lung dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: WOMAC knee pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target vessel-related myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Late/very late definite/probable stent thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: M6G concentrations in codeine dose groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of agitation, tremors and excitation from morphine administration
Endpoint domain: Adverse events/effects
Primary endpoint: Antidepressant-like effect measured by HDRS-24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antidepressant-like effect measured by MADRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serum serotonin turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants tested for HIV by 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants tested for HIV between 7 and 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal retention rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Surgeon discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Mean total administration time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device contamination rate
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of prosthetic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Flunixin meglumine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thromboxane B2 suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostaglandin E2 decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pCO2 elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: enteral feeding issues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to removal of the abdominal drain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: reduced risk of death or cardiovascular hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: reduced risk of cardiovascular death or heart failure hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: cumulative risk of stroke
Endpoint domain: Adverse events/effects
Primary endpoint: late risk of reinterventions
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of PPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Engagement with offered assistance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: time to disengagement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NAD+ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in infant feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in active play
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in sedentary behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: height of the intervertebral space
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: height of the intervertebral foramen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PDQ-39 performance
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 9-Hole Peg test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence rates for digital CBT-i
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in SIS physical problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gastroduodenal mucosal breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients who attempted suicide
Endpoint domain: Mortality/survival
Primary endpoint: Rate of histologic improvement in liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Liver stiffness measurement (LSM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Proportion of survivors meeting MVPA guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: withholding of fortification for 24 hours or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: RCB-0/1 rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental blood glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: average loss of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increase in relative VO2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: KSS and HSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid consumption in PCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of PCA compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesia during postoperative time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: conjunctival hyperaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of IL-1α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic accuracy for AOM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for learning modality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breast Cancer Recurrence symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean reduction in monthly migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction of Headache Impact Test‐6 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with severe headache-related disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cognitive function improvement (MoCA scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep quality improvement (PSQI scores)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Positive rate of BPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity of BPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Vessel diameter increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: sufentanil consumption at 24 h after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative Numerical Rating Scale (NRS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days of methamphetamine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: methamphetamine-positive oral fluid samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue domain of the quality of life index
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: serum albumin, prealbumin and haemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAS scores of hypogastrium and lumbosacral region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of local signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological scores of WHOQOL-BREF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Positive sexual self-concept score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sexual quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: National Institutes of Health Stroke Scale score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean infarct growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean QOL scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: minimum oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SCR score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events Rate (ADR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation Spasm Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Withdrawal Spasm Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Polypectomy Spasm Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AK clearance and prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: excellent functional outcome (mRS ≤ 1) at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall distribution of scores on the modified Rankin scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of primary safety endpoint events (sICH) in 90 days
Endpoint domain: Adverse events/effects
Primary endpoint: Seroconversion rates of antibodies against EV71
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mortality at 14 days post-stroke
Endpoint domain: Mortality/survival
Primary endpoint: static Physician Global Assessment response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ubrogepant Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0–inf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥30% reduction in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: perimenopausal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Future exacerbation risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LDL-C variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: First acute arterial events
Endpoint domain: Mortality/survival
Primary endpoint: Change in PVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Borg dyspnoea scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Head penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermatology Life Quality Index (DLQI) 0/1 response
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Urine albumin-creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: simulated performance scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interest in orthopaedic surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Migraine disability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 7-point scale symptom severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RQLQs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: postprandial concentrations of oxidised glutathione
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial concentrations of reduced glutathione
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in prescriptions for statins or antihypertensive medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in understanding of disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rates of CDC-defined deep SSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: accuracy of working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of nasal ala pressure injuries
Endpoint domain: Adverse events/effects
Primary endpoint: cumulative incisal and cervical measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prince Henry pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of CLABSI per 1000 central line days
Endpoint domain: Adverse events/effects
Primary endpoint: Serum vitamin B-12 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone turnover markers balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ-5D questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Polymorphism among accessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to discontinue HOT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Zygomatic implant survival rate
Endpoint domain: Mortality/survival
Primary endpoint: BPI scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cutaneous sclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety remission
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of postoperative urinary retention (POUR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease of body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease of visceral adipose tissue (VAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tenderness value improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lysholm knee function score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utilization of dental services
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Patent hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Crossover rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Median hemostasis time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: pre‐interventional reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemolysis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioavailability of TMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drug distribution in spinal cord tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: School engagement level
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Risk of HE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Proportion of participants living at home
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of participants in long-term residential care
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: urea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incidence of postoperative nausea and vomiting (PONV)
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative 48-hour numeric rating scale (NRS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent tonsillitis
Endpoint domain: Mortality/survival
Primary endpoint: Mean percentage of online lunch items that were 'Everyday'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage of online lunch items that were 'Should not be sold'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival of the implant
Endpoint domain: Mortality/survival
Primary endpoint: implant alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Illness recognition of substance use disorder
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived severity of substance use
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Exacerbations over 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food impact
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in the opening range of the mouth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain-free walking distance (PWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IS (Infarct Size)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MVO (Microvascular Obstruction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative success probability
Endpoint domain: Mortality/survival
Primary endpoint: self-care maintenance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core temperature during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise-induced plasma interleukin-6 (IL-6) elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum hepcidin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes